REMoDL-B研究5年随访:根据弥漫大B细胞淋巴瘤分子亚组分析硼替佐米联合R-CHOP的疗效差异
REMoDL-B是一项III期适应性试验,比较R-CHOP与R-CHOP联合硼替佐米(RB-CHOP)在弥漫大B细胞淋巴瘤(DLBCL)患者中的疗效,按分子亚型分层。中位随访64个月时,硼替佐米对无进展生存(PFS)或总生存(OS)无总体获益(5年PFS风险比HR 0.81,P=0.085;OS HR 0.86,P=0.32)。但在ABC亚型中,RB-CHOP组5年OS为80% vs R-CHOP组67%(HR 0.58,95%CI 0.35-0.95,P=0.032);在MHG亚型中,5年PFS为55% vs 29%(HR 0.46,95%CI 0.26-0.84)。作者认为ABC和MHG亚型DLBCL患者可能从初始化疗加入硼替佐米中获益。
要点
- 中位随访64个月,硼替佐米对整体人群PFS和OS无显著获益(5年PFS HR 0.81,P=0.085;OS HR 0.86,P=0.32)。
- ABC亚型中RB-CHOP组5年OS为80% vs R-CHOP组67%(HR 0.58,95%CI 0.35-0.95,P=0.032)。
- MHG亚型中RB-CHOP组5年PFS为55% vs R-CHOP组29%(HR 0.46,95%CI 0.26-0.84)。
核心结论
- 在整体DLBCL人群中,RB-CHOP较R-CHOP未显示PFS或OS显著获益。
- ABC亚型患者中RB-CHOP组5年OS高于R-CHOP组(80% vs 67%,HR 0.58,95%CI 0.35-0.95,P=0.032)。
- MHG亚型患者中RB-CHOP组5年PFS高于R-CHOP组(55% vs 29%,HR 0.46,95%CI 0.26-0.84)。
- 作者认为ABC和MHG亚型DLBCL患者可能从初始化疗加入硼替佐米中获益。
研究设计与样本
- REMoDL-B为III期适应性试验,比较R-CHOP与RB-CHOP,按分子亚型分层。
- 纳入年龄大于18岁、未经治疗、适合全剂量化疗且有足够活检组织进行基因表达谱(GEP)检测的DLBCL患者。
- 注册1077例患者,其中801例成功分型为ABC、生发中心B细胞或MHG淋巴瘤。
- 本次更新分析针对经GEP成功分型的患者,中位随访64个月。
主要发现
- 中位随访64个月,硼替佐米对整体人群PFS或OS无总体获益(5年PFS HR 0.81,P=0.085;OS HR 0.86,P=0.32)。
- ABC亚型中,RB-CHOP组5年OS为80% vs R-CHOP组67%(HR 0.58,95%CI 0.35-0.95,P=0.032),RB-CHOP组PFS和OS改善。
- MHG亚型中,RB-CHOP组5年PFS为55% vs R-CHOP组29%(HR 0.46,95%CI 0.26-0.84),RB-CHOP组PFS更高。
临床怎么用
- 作者认为ABC和MHG亚型DLBCL患者可能从初始化疗加入硼替佐米中获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The REMoDL-B phase III adaptive trial compared rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) versus R-CHOP + bortezomib (RB-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL), stratified by molecular subtype. Primary analysis at a median follow-up of 30 months found no effect of bortezomib on progression-free survival (PFS) or overall survival (OS). Retrospective analysis using a gene expression-based classifier identified a molecular high-grade (MHG) group with worse outcomes. We present an updated analysis for patients successfully classified by the gene expression profile (GEP). Eligible patients were age older than 18 years with untreated DLBCL, fit enough for full-dose chemotherapy, and with adequate biopsies for GEP. Of 1,077 patients registered, 801 were identified with Activated B-Cell (ABC), Germinal Center B-cell, or MHG lymphoma. At a median follow-up of 64 months, there was no overall benefit of bortezomib on PFS or OS (5-year PFS hazard ratio [HR], 0.81; P = .085; OS HR, 0.86; P = .32). However, improved PFS and OS were seen in ABC lymphomas after RB-CHOP: 5-year OS 67% with R-CHOP versus 80% with RB-CHOP (HR, 0.58; 95% CI, 0.35 to 0.95; P = .032). Five-year PFS was higher in MHG lymphomas: 29% versus 55% (HR, 0.46; 95% CI, 0.26 to 0.84). Patients with ABC and MHG DLBCL may benefit from the addition of bortezomib to R-CHOP in initial therapy.
引用
- Davies AJ, Barrans S, Stanton L, et al. Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up. J Clin Oncol. 2023. PMID: 36972491. doi:10.1200/JCO.23.00033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。